Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias

We investigated the efficacy of targeting the PIM kinase pathway in Philadelphia chromosome-positive (Ph+) leukemias. We provide evidence that inhibition of PIM, with the pan-PIM inhibitor SGI-1776, results in suppression of classic PIM effectors and also elements of the mTOR pathway, suggesting int...

Descripción completa

Detalles Bibliográficos
Autores principales: Curi, Dany A., Beauchamp, Elspeth M., Blyth, Gavin T., Arslan, Ahmet Dirim, Donato, Nicholas J., Giles, Francis J., Altman, Jessica K., Platanias, Leonidas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741759/
https://www.ncbi.nlm.nih.gov/pubmed/26375673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741759/
https://www.ncbi.nlm.nih.gov/pubmed/26375673

Ejemplares similares